Association of pretransplant serum phosphorus with posttransplant outcomes

Clinical Journal of the American Society of Nephrology

Volumn 6, Issue 11, 2011, Pages 2712-2721

  Sampaio, Marcelo S ^a   Molnar, Miklos Z ^a,b   Kovesdy, Csaba P ^c,d   Mehrotra, Rajnish ^e   Mucsi, Istvan ^f   Sim, John J ^g   Krishnan, Mahesh ^h   Nissenson, Allen R ^h   Kalantar Zadeh, Kamyar ^a,c,e  

^a LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE   (United States)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c UNIVERSITY OF VIRGINIA   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^g KAISER PERMANENTE   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHORUS;

ADULT; ARTICLE; CONTROLLED STUDY; DIALYSIS; DISEASE ASSOCIATION; FEMALE; GRAFT FAILURE; HUMAN; KIDNEY ALLOGRAFT; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PHOSPHATE BLOOD LEVEL; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; REGISTER; RISK ASSESSMENT;

ADULT; AGED; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; DELAYED GRAFT FUNCTION; FEMALE; HUMANS; KIDNEY TRANSPLANTATION; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PHOSPHORUS; PREOPERATIVE PERIOD; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TISSUE AND ORGAN PROCUREMENT; TREATMENT OUTCOME; UNITED STATES;

EID: 80655139675     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.06190611     Document Type: Article

References (51)

1. Block GA, Hulbert-Shearon TE, Levin NW, Port FK: Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 31: 607-617, 1998
2. Block GA: Prevalence and clinical consequences of elevated Ca x P product in hemodialysis patients. Clin Nephrol 54: 318-324, 2000
3. Slinin Y, Foley RN, Collins AJ: Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: The USRDS waves 1, 3, and 4 study. J Am Soc Nephrol 16: 1788-1793, 2005
4. Voormolen N, Noordzij M, Grootendorst DC, Beetz I, Sijpkens YW, van Manen JG, Boeschoten EW, Huisman RM, Krediet RT, Dekker FW: High plasma phosphate as a risk factor for decline in renal function and mortality in predialysis patients. Nephrol Dial Transplant 22: 2909-2916, 2007
5. Schwarz S, Trivedi BK, Kalantar-Zadeh K, Kovesdy CP: Association of disorders in mineral metabolism with progression of chronic kidney disease. Clin J Am Soc Nephrol 1: 825-831, 2006
6. Kovesdy CP, Anderson JE, Kalantar-Zadeh K: Outcomes associated with serum phosphorus level in males with non-dialysis dependent chronic kidney disease. Clin Nephrol 73: 268-275, 2010
7. Block GA: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15: 2208-2218, 2004
8. Cunningham J, Silver J: CKD-MBD: Comfort in the trough of the U. Nephrol Dial Transplant 26: 1764-1766, 2011
9. Qunibi W, Kalantar-Zadeh K: Target levels for serum phosphorus and parathyroid hormone. Semin Dial 24: 29-33, 2011
10. Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J, Young EW, Akizawa T, Akiba T, Pisoni RL, Robinson BM, Port FK: Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: The Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 52: 519-530, 2008
11. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42: S1-S201, 2003
12. Cozzolino M, Dusso AS, Slatopolsky E: Role of calcium-phosphate product and bone-associated proteins on vascular calcification in renal failure. J Am Soc Nephrol 12: 2511-2516, 2001
13. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK: Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 12: 2131-2138, 2001
14. Fujiu A, Ogawa T, Matsuda N, Ando Y, Nitta K: Aortic arch calcification and arterial stiffness are independent factors for diastolic left ventricular dysfunction in chronic hemodialysis patients. Circ J 72: 1768-1772, 2008
15. Nitta K, Akiba T, Uchida K, Otsubo S, Otsubo Y, Takei T, Ogawa T, Yumura W, Kabaya T, Nihei H: Left ventricular hypertrophy is associated with arterial stiffness and vascular calcification in hemodialysis patients. Hypertens Res 27: 47-52, 2004
16. London GM: Cardiovascular disease in chronic renal failure: Pathophysiologic aspects. Semin Dial 16: 85-94, 2003
17. Fatica RA, Dennis VW: Cardiovascular mortality in chronic renal failure: Hyperphosphatemia, coronary calcification, and the role of phosphate binders. Cleve Clin J Med 69 [Suppl 3]: S21-S27, 2002
18. Roe P, Wolfe M, Joffe M, Rosas SE: Inflammation, coronary artery calcification and cardiovascular events in incident renal transplant recipients. Atherosclerosis 212: 589-594, 2010
19. Santos RD: Coronary artery calcification progression and cardiovascular events in renal transplant recipients, bad inheritance from previous kidney disease: Commentary on the study of Roe et al. Atherosclerosis 212: 390-391, 2010
20. Levi M: Post-transplant hypophosphatemia. Kidney Int 59: 2377-2387, 2001
21. Evenepoel P, Meijers BKI, de Jonge H, Naesens M, Bammens B, Claes K, Kuypers D, Vanrenterghem Y: Recovery of hyper-phosphatoninism and renal phosphorus wasting one year after successful renal transplantation. Clin J Am Soc Nephrol 3: 1829-1836, 2008
22. Vervaet BA, Verhulst A, D'Haese PC, De Broe ME: Nephrocalcinosis: New insights into mechanisms and consequences. Nephrol Dial Transplant 24: 2030-2035, 2009
23. Evenepoel P, Lerut E, Naesens M, Bammens B, Claes K, Kuypers D, Vermeersch P, Meijers B, Van Damme B, Vanrenterghem Y: Localization, etiology and impact of calcium phosphate deposits in renal allografts. Am J Transplant 9: 2470-2478, 2009
24. Chang PC, Saha S, Gomes AM, Padiyar A, Bodziak KA, Poggio ED, Hricik DE, Augustine JJ: Donor phosphorus levels and recipient outcomes in living-donor kidney transplantation. Clin J Am Soc Nephrol 6: 1179-1184, 2011
25. Duong U, Mehrotra R, Molnar MZ, Noori N, Kovesdy CP, Nissenson AR, Kalantar-Zadeh K: Glycemic control and survival in peritoneal dialysis patients with diabetes mellitus. Clin J Am Soc Nephrol 6: 1041-1048, 2011
26. Molnar MZ, Lukowsky LR, Streja E, Dukkipati R, Jing J, Nissenson AR, Kovesdy CP, Kalantar-Zadeh K: Blood pressure and survival in long-term hemodialysis patients with and without polycystic kidney disease. J Hypertens 28: 2475-2484, 2010
27. Miller JE, Kovesdy CP, Nissenson AR, Mehrotra R, Streja E, Van Wyck D, Greenland S, Kalantar-Zadeh K: Association of hemodialysis treatment time and dose with mortality and the role of race and sex. Am J Kidney Dis 55: 100-112, 2010
28. Miller JE, Kovesdy CP, Norris KC, Mehrotra R, Nissenson AR, Kopple JD, Kalantar-Zadeh K: Association of cumulatively low or high serum calcium levels with mortality in long-term hemodialysis patients. Am J Nephrol 32: 403-413, 2010
29. Kalantar-Zadeh K, Miller JE, Kovesdy CP, Mehrotra R, Lukowsky LR, Streja E, Ricks J, Jing J, Nissenson AR, Greenland S, Norris KC: Impact of race on hyperparathyroidism, mineral disarrays, administered vitamin D mimetic, and survival in hemodialysis patients. J Bone Miner Res 25: 2448-2458, 2010
30. Kalantar-Zadeh K, Streja E, Kovesdy CP, Oreopoulos A, Noori N, Jing J, Nissenson AR, Krishnan M, Kopple JD, Mehrotra R, Anker SD: The obesity paradox and mortality associated with surrogates of body size and muscle mass in patients receiving hemodialysis. Mayo Clin Proc 85: 991-1001, 2010
31. Molnar MZ, Kovesdy CP, Bunnapradist S, Streja E, Mehrotra R, Krishnan M, Nissenson AR, Kalantar-Zadeh K: Associations of pretransplant serum albumin with post-transplant outcomes in kidney transplant recipients. Am J Transplant 11: 1006-1015, 2011
32. Yarlagadda SG, Coca SG, Garg AX, Doshi M, Poggio E, Marcus RJ, Parikh CR: Marked variation in the definition and diagnosis of delayed graft function: A systematic review. Nephrol Dial Transplant 23: 2995-3003, 2008
33. Shinaberger CS, Greenland S, Kopple JD, Van Wyck D, Mehrotra R, Kovesdy CP, Kalantar-Zadeh K: Is controlling phosphorus by decreasing dietary protein intake beneficial or harmful in persons with chronic kidney disease? Am J Clin Nutr 88: 1511-1518, 2008
34. Molnar MZ, Streja E, Kovesdy CP, Bunnapradist S, Sampaio MS, Jing J, Krishnan M, Nissenson AR, Danovitch GM, Kalantar-Zadeh K: Associations of body mass index and weight loss with mortality in transplant-waitlisted maintenance hemodialysis patients. Am J Transplant 11: 725-736, 2011
35. Abedi SA, Tarzamni MK, Nakhjavani MR, Bohlooli A: Effect of renal transplantation on coronary artery calcification in hemodialysis patients. Transplant Proc 41: 2829-2831, 2009
36. Yulia M, Ronen L, Vardit L-M, Keith BC, Jeffery DM, Justin S, Tally N-M: Calcineurin Abeta is central to the expression of the renal type II Na/Pi co-transporter gene and to the regulation of renal phosphate transport. J Am Soc Nephrol 15: 2972-2980, 2004
37. Schwarz C, Bohmig GA, Steininger R, Mayer G, Oberbauer R: Impaired phosphate handling of renal allografts is aggravated under rapamycin-based immunosuppression. Nephrol Dial Transplant 16: 378-382, 2001
38. Riella LV, Rennke HG, Grafals M, Chandraker A: Hypophos-phatemia in kidney transplant recipients: Report of acute phosphate nephropathy as a complication of therapy. Am J Kidney Dis 57: 641-645, 2011
39. Khan SR: Crystal-induced inflammation of the kidneys: Results from human studies, animal models, and tissue-culture studies. Clin Exp Nephrol 8: 75-88, 2004
40. Umekawa T, Chegini N, Khan SR: Increased expression of monocyte chemoattractant protein-1 (MCP-1) by renal epithelial cells in culture on exposure to calcium oxalate, phosphate and uric acid crystals. Nephrol Dial Transplant 18: 664-669, 2003
41. Roodnat JI, van Gurp EA, Mulder PG, van Gelder T, de Rijke YB, de Herder WW, Kal-van Gestel JA, Pols HA, Ijzermans JN, Weimar W: High pretransplant parathyroid hormone levels increase the risk for graft failure after renal transplantation. Transplantation 82: 362-367, 2006
42. Rodrigo Calabia E, Ruiz San Millan JC, Gago M, Ruiz Criado J, Pinera Haces C, Fernandez Fresnedo G, Palomar R, Gomez Alamillo C, Martin de Francisco AL, Arias M: [Changes in the pre-transplant bone-mineral metabolism do not affect the initial progress of the renal graft]. Nefrologia 29: 143-149, 2009
43. Schaeffner ES, Fodinger M, Kramar R, Sunder-Plassmann G, Winkelmayer WC: Prognostic associations of serum calcium, phosphate and calcium phosphate concentration product with outcomes in kidney transplant recipients. Transpl Int 20: 247-255, 2007
44. Connolly GM, Cunningham R, McNamee PT, Young IS, Maxwell AP: Elevated serum phosphate predicts mortality in renal transplant recipients. Transplantation 87: 1040-1044, 2009
45. Stevens KK, Morgan IR, Patel RK, Geddes CC, Mark PB, Jardine AG, Delles C: Serum phosphate and outcome at one year after deceased donor renal transplantation. Clin Transplant 25: E199-E204, 2011
46. Wesseling-Perry K, Tsai EW, Ettenger RB, Juppner H, Salusky IB: Mineral abnormalities and long-term graft function in pediatric renal transplant recipients: A role for FGF-23? Nephrol Dial Transplant 2011, in press
47. Wolf M, Molnar MZ, Amaral AP, Czira ME, Rudas A, Ujszaszi A, Kiss I, Rosivall L, Kosa J, Lakatos P, Kovesdy CP, Mucsi I: Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. J Am Soc Nephrol 22: 956-966, 2011
48. Kovesdy CP, Kuchmak O, Lu JL, Kalantar-Zadeh K: Outcomes associated with phosphorus binders in men with non-dialysis-dependent CKD. Am J Kidney Dis 56: 842-851, 2010
49. Shantouf R, Ahmadi N, Flores F, Tiano J, Gopal A, Kalantar-Zadeh K, Budoff MJ: Impact of phosphate binder type on coronary artery calcification in hemodialysis patients. Clin Nephrol 74: 12-18, 2010
50. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R: Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 349: 446-456, 2003
51. Taylor LM, Kalantar-Zadeh K, Markewich T, Colman S, Benner D, Sim JJ, Kovesdy CP: Dietary egg whites for phosphorus control in maintenance haemodialysis patients: A pilot study. J Ren Care 37: 16-24, 2011